View Older Stories View More Recent Stories

Apr 1, 2021 08:35AM Merck (MRK) Completes Acquisition of Pandion Therapeutics (PAND)
Apr 1, 2021 08:30AM Merck Completes Acquisition of Pandion Therapeutics
Mar 30, 2021 07:34AM Merck (MRK) Announces Acquisition of Alydia Health on behalf of its Planned Spinoff of Organon
Mar 30, 2021 07:30AM Merck Announces Acquisition of Alydia Health on behalf of its Planned Spinoff of Organon
Mar 30, 2021 06:46AM Merck (MRK) Receives Positive EU CHMP Opinion for Updated Label of KEYTRUDA To Include Results of Phase 3 KEYNOTE-361 Trial in Certain Adult Patients with Locally Advanced or Metastatic Urothelial Can
Mar 30, 2021 06:45AM Merck Receives Positive EU CHMP Opinion for Updated Label of KEYTRUDA® (pembrolizumab) To Include Results of Phase 3 KEYNOTE-361 Trial in Certain Adult Patients with Locally Advanced or Metastatic Ur
Mar 29, 2021 04:16PM Merck (MRK) Receives CRL From US FDA for Supplemental Biologics License Application for KEYTRUDA in High-Risk Early-Stage TNBC
Mar 29, 2021 04:15PM Merck Receives Complete Response Letter From US FDA for Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
Mar 29, 2021 06:45AM Merck to Hold First-Quarter 2021 Sales and Earnings Conference Call on April 29
Mar 24, 2021 06:45AM Merck (MRK) Appoints Caroline Litchfield as CFO
Mar 24, 2021 06:45AM Merck Appoints Caroline Litchfield Chief Financial Officer
Mar 23, 2021 06:50AM FDA Approves Merck’s (MRK) KEYTRUDA Plus Platinum- and Fluoropyrimidine-Based Chemotherapy for Treatment of Certain Patients With Locally Advanced or Metastatic Esophageal or GEJ Carcinoma
Mar 23, 2021 06:45AM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Platinum- and Fluoropyrimidine-Based Chemotherapy for Treatment of Certain Patients With Locally Advanced or Metastatic Esophageal or Gastroesoph
Mar 19, 2021 06:46AM Merck (MRK) Announces KEYTRUDA Plus LENVIMA Significantly Improved PFS and OS Versus Chemotherapy in Patients With Advanced Endometrial Cancer
Mar 19, 2021 06:45AM KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Significantly Improved Progression-Free Survival and Overall Survival Versus Chemotherapy in Patients With Advanced Endometrial Cancer Following
Mar 17, 2021 04:28PM Merck (MRK) Files Form 10 Related to Planned Spinoff of Organon & Co.
Mar 17, 2021 04:27PM Merck Announces Filing of Form 10 Registration Statement in Connection with Planned Spinoff of Organon & Co.
Mar 17, 2021 11:40AM MilliporeSigma Accelerates European Expansion Plans for Single-use Products Critical to Manufacturing Vaccines and Lifesaving Therapies
Mar 17, 2021 07:03AM EC Approves Expanded Indication for Merck’s (MRK) KEYTRUDA in Adult and Pediatric Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Mar 17, 2021 07:00AM European Commission Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) in Adult and Pediatric Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)
Mar 17, 2021 06:45AM Mike Nally to Leave Merck; Frank Clyburn to Lead All Merck Human Health
Mar 16, 2021 06:45AM Merck (MRK) Receives Priority Review From FDA for New Drug Application for HIF-2α Inhibitor Belzutifan
Mar 16, 2021 06:45AM Merck Receives Priority Review From FDA for New Drug Application for HIF-2α Inhibitor Belzutifan (MK-6482)
Mar 15, 2021 06:47AM Merck to Host Investor Briefing to Discuss Broad HIV Development Program and Newly Announced Collaboration with Gilead
Mar 15, 2021 06:46AM Gilead (GILD), Merck (MRK) Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV
Mar 15, 2021 06:45AM Gilead and Merck Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV
Mar 8, 2021 11:40AM Merck (MRK) Presents Results from Phase 1 Trial Evaluating Investigational Islatravir Subdermal Implant for the Prevention of HIV-1 Infection at CROI 2021
Mar 8, 2021 11:40AM Merck Presents Results from Phase 1 Trial Evaluating Investigational Islatravir Subdermal Implant for the Prevention of HIV-1 Infection at CROI 2021
Mar 6, 2021 12:01AM Ridgeback Biotherapeutics and Merck Announce Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir
Mar 4, 2021 06:48AM Merck (MRK) Begins Tender Offer to Acquire Pandion Therapeutics (PAND)
Mar 4, 2021 06:45AM Merck Begins Tender Offer to Acquire Pandion Therapeutics
Mar 3, 2021 06:45AM Merck to Present at the Barclays Global Healthcare Conference
Mar 3, 2021 06:45AM Merck to Present New Data from Various HIV Research and Development Programs at CROI 2021
Mar 2, 2021 04:32PM Merck (MRK) Confirms It Will Help Produce Johnson & Johnson’s (JNJ) COVID-19 Vaccine;
Mar 2, 2021 04:30PM Merck to Help Produce Johnson & Johnson’s COVID-19 Vaccine; BARDA to Provide Merck With Funding to Expand Merck’s Manufacturing Capacity for COVID-19 Vaccines and Medicines
Mar 2, 2021 08:00AM Merck Announces Fifth Round of Global Grants to Tackle Maternal Mortality and Promote Health Equity Worldwide
Mar 1, 2021 04:12PM Merck (MRK) Provides Update on KEYTRUDA Indication in Metastatic Small Cell Lung Cancer in the US
Mar 1, 2021 04:05PM Merck Provides Update on KEYTRUDA® (pembrolizumab) Indication in Metastatic Small Cell Lung Cancer in the US
Mar 1, 2021 06:46AM Merck (MRK) Announces U.S. FDA Accepts its Gefapixant New Drug Application for Review
Mar 1, 2021 06:45AM U.S. FDA Accepts Merck’s Gefapixant New Drug Application for Review
Feb 25, 2021 04:30PM Merck Animal Health Completes Acquisition of Poultry Sense Limited
Feb 25, 2021 06:46AM Merck (MRK) to Acquire Pandion Therapeutics (PAND) for $60/Share in $1.85 Billion Deal
Feb 25, 2021 06:45AM Merck to Acquire Pandion Therapeutics
Feb 24, 2021 06:45AM Merck to Present at the Cowen 41st Annual Health Care Conference
Feb 17, 2021 06:59AM AstraZeneca (AZN), Merck (MRK) Announce IDMC Concludes OlympiA Trial of LYNPARZA Crossed Superiority Boundary for Invasive Disease-Free Survival vs. Placebo at Planned Interim Analysis
Feb 17, 2021 06:55AM Independent Data Monitoring Committee Concludes OlympiA Trial of LYNPARZA® (olaparib) Crossed Superiority Boundary for Invasive Disease-Free Survival vs. Placebo at Planned Interim Analysis
Feb 13, 2021 01:01PM KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrated Superior Progression-Free Survival (PFS) and Overall Survival (OS) Versus Sunitinib as First-Line Treatment for Patients With Advanc
Feb 4, 2021 06:45AM Merck Announces Fourth-Quarter and Full-Year 2020 Financial Results
Feb 4, 2021 06:41AM Merck (MRK) CEO Kenneth C. Frazier to Retire; Board Elects Robert M. Davis as Successor; Frazier to Continue as Executive Chairman
Feb 4, 2021 06:40AM Kenneth C. Frazier to Retire as Merck CEO; Board Elects Robert M. Davis as Successor; Frazier to Continue as Executive Chairman
View More Recent Stories View Older Stories